Quanterix

United States
Billerica, Massachusetts, United States, 01821

Company profile

Quanterix company profile

Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.

Business identity

Contact email
[email protected]
Phone number
617-301-9400
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$10M-$100M
Founded
2007-01-01, Year

Headquarters

Postal code
01821
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$531.3M
Last funding
Grant / 2022-03-29
Last equity funding
Post IPO Equity / $287.5M
Investors
12
Lead investors
10
Founders
1
Articles
354
Exited on
2017-12-06

Founders and investors

Founders

David R. Walt

Lead investors

Alzheimer's Drug Discovery FoundationARCH Overage FundARCH Venture PartnersBain Capital VenturesbioMerieuxCormorant Asset ManagementFlagship PioneeringIQTTrinitas CapitalT. Rowe Price

Investors

ARCH Venture PartnersBain Capital VenturesCormorant Asset ManagementFlagship PioneeringHercules Capital